Misinterpretation of the “Overdose Crisis” Continues to Fuel Misunderstanding of the Role of Prescription Opioids

References

• Centers for Disease Control and Prevention. CDC national center for health statistics: provisional drug overdose death counts [Internet]. Available from: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm#dashboard. Accessed February 2022.
   Google Scholar
• O’Donnell J, Tanz LJ, Gladden RM, et al. Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls — United States, 2019–2020. MMWR Morb Mortal Wkly Rep. 2021;70(50):1740–1746. doi:10.15585/mmwr.mm7050e3
   PubMed Web of Science ®Google Scholar
• Jones CM, Bekheet F, Park JN, Alexander GC. The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms. Epidemiol Rev. 2020;42:154–166. doi:10.1093/epirev/mxaa011
   PubMed Web of Science ®Google Scholar
• Timko C, Han X, Woodhead E, Shelley A, Cucciare MA. Polysubstance use by stimulant users: health outcomes over three years. J Stud Alcohol Drugs. 2018;79:799–807. doi:10.15288/jsad.2018.79.799
   PubMed Web of Science ®Google Scholar
• O’Donnell J, Gladden RM, Mattson CL, Hunter CT, Davis NL. Vital signs: characteristics of drug overdose deaths involving opioids and stimulants—24 states and the District of Columbia, January–June 2019. MMWR Morb Mortal Wkly Rep. 2020;69:1189–1197. doi:10.15585/mmwr.mm6935a1
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2020. Data on substance abuse treatment facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2021. Available from: https://www.samhsa.gov/data/sites/default/files/reports/rpt35313/2020_NSSATS_FINAL.pdf. Accessed March 30, 2022.
   Google Scholar
• Kroenke K, Alford DP, Argoff C, et al. Challenges with implementing the centers for disease control and prevention opioid guideline: a consensus panel report. Pain Med. 2019;20(4):724–735. doi:10.1093/pm/pny307
   PubMed Web of Science ®Google Scholar
• Darnall BD, Juurlink D, Kerns RD, et al. International stakeholder community of pain experts and leaders call for an urgent action on forced opioid tapering. Pain Med. 2019;20(3):429–433. doi:10.1093/pm/pny228
   PubMed Web of Science ®Google Scholar
• Behar E, Bagnulo R, Knight K, et al. “Chasing the pain relief, not the high”: experiences managing pain after opioid reductions among patients with HIV and a history of substance use. PLoS One. 2020;15(3):e0230408. doi:10.1371/journal.pone.0230408
   PubMed Web of Science ®Google Scholar
• Oliva EM, Bowe T, Manhapra A, et al. Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ. 2020;368:m283. doi:10.1136/bmj.m283
   PubMed Web of Science ®Google Scholar
• Agnoli A, Xing G, Tancredi DJ, et al. Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids. JAMA. 2021;326(5):411–419. doi:10.1001/jama.2021.11013
   PubMed Web of Science ®Google Scholar
• Metzer S. Testimony of “paid expert” questioned by drugmaker [Internet]. The Journal Record; 2019. Available from: https://journalrecord.com/2019/06/17/testimony-of-paid-expert-questioned-by-drugmaker/. Accessed February 2022.
   Google Scholar
• PROP News Release. Prescription opioids continue to contribute to the rise in drug overdose deaths [Internet]. PROP; 2021. Available from: http://www.supportprop.org/opioid-news/prop-news-release-prescription-opioids-continue-to-contribute-to-the-rise-in-drug-overdose-deaths/. Accessed February 2022.
   Google Scholar
• O’Donnell J, Gladden RM, Kariisa M, Mattson CL. Using death scene and toxicology evidence to define involvement of heroin, pharmaceutical morphine, illicitly manufactured fentanyl and pharmaceutical fentanyl in opioid overdose deaths, 38 states and the District of Columbia, January 2018-December 2019. Addiction. 2021. doi:10.1111/add.15768
   Web of Science ®Google Scholar
• Persico AL, Wegrzyn EL, Fudin J, Schatman ME. Fentalogues. J Pain Res. 2020;13:2131–2133. doi:10.2147/JPR.S265901
   PubMed Web of Science ®Google Scholar
• Peppin JF, Raffa RB, Schatman ME. The polysubstance overdose-death crisis. J Pain Res. 2020;13:3405–3408. doi:10.2147/JPR.S295715
   PubMed Web of Science ®Google Scholar
• Piro L, Martinotti SG, Vannini R, et al. Substance screening in a sample of “clubbers”: discrepancies between self-reporting and urinalysis. Evid Based Psychiatric Care. 1954;120:10.
   Google Scholar
• Baselt RC, Allison DJ, Wright JA, Scannell JR, Stephens BG. Acute heroin fatalities in San Francisco. Demographic and toxicologic characteristics. West J Med. 1975;122(6):455–458.
   PubMedGoogle Scholar
• Taylor A, Frischer M, Goldberg D. Non-fatal overdosing is related to polydrug use in Glasgow. BMJ. 1996;313(7069):1400–1401. doi:10.1136/bmj.313.7069.1400b
   PubMed Web of Science ®Google Scholar
• Coffin PO, Galea S, Ahern J, Leon AC, Vlahov D, Tardiff K. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990–98. Addiction. 2003;98(6):739–747. doi:10.1046/j.1360-0443.2003.00376.x
   PubMed Web of Science ®Google Scholar
• Strang P, Griffiths P, Powis B, Fountain J, Williamson S, Gossop M. Which drugs cause overdose among opiate misusers? Study of personal and witnessed overdoses. Drug Alcohol Rev. 1999;18(3):253–261. doi:10.1080/09595239996383
   Web of Science ®Google Scholar
• Cone EJ, Fant RV, Rohay JM, et al. Oxycodone involvement in drug abuse deaths: a Dawn-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol. 2003;27(2):57–67; discussion 67. doi:10.1093/jat/27.2.57
   Web of Science ®Google Scholar
• Cone EJ, Fant RV, Rohay JM, et al. Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions. J Anal Toxicol. 2004;28(4):217–225. doi:10.1093/jat/28.4.217
   PubMed Web of Science ®Google Scholar
• Shah NG, Lathrop SL, Reichard RR, Landen MG. Unintentional drug overdose death trends in New Mexico, USA, 1990–2005: combinations of heroin, cocaine, prescription opioids and alcohol. Addiction. 2008;103(1):126–136. doi:10.1111/j.1360-0443.2007.02054.x
   PubMed Web of Science ®Google Scholar
• NYC Department of Health and Mental Hygiene. Illicit drug use in New York City. NYC Vital Signs. 2010;9(1):1–4.
   Google Scholar
• Hannah HA, Arambula K, Ereman R, Harris D, Torres A, Willis M. Using local toxicology data for drug overdose mortality surveillance. Online J Public Health Inform. 2017;9(1):e143. doi:10.5210/ojphi.v9i1.7733
   Google Scholar
• Seth P, Rudd RA, Noonan RK, Haegerich TM. Quantifying the epidemic of prescription opioid overdose deaths. Am J Public Health. 2018;108(4):500–502. doi:10.2105/AJPH.2017.304265
   PubMed Web of Science ®Google Scholar
• Friedman J, Akre S. COVID-19 and the drug overdose crisis: uncovering the deadliest months in the United States, January‒July 2020. Am J Public Health. 2021;111:1284–1291. doi:10.2105/AJPH.2021.306256
   PubMed Web of Science ®Google Scholar
• CDC Drug Overdose. US opioid dispensing rate map [Internet]. CDC; 2021. Available from: https://www.cdc.gov/drugoverdose/rxrate-maps/index.html. Accessed February 2022.
   Google Scholar
• Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013–2019. MMWR Morb Mortal Wkly Rep. 2021;70:202–207. doi:10.15585/mmwr.mm7006a4
   PubMed Web of Science ®Google Scholar
• Fudin J, Raouf M. Alternative opioid facts and the new banana republic [Internet]. Paindr.com; 2017. Available from: https://paindr.com/alternative-opioid-facts-and-the-new-banana-republic/. Accessed February 2022.
   Google Scholar
• Schatman ME, Shapiro H. Damaging state legislation regarding opioids: the need to scrutinize sources of inaccurate information provided to lawmakers. J Pain Res. 2019;12:3049–3053. doi:10.2147/JPR.S235366
   PubMed Web of Science ®Google Scholar
• Kertesz SG, Satel SL, DeMicco J, Dart RC, Alford DP. Opioid discontinuation as an institutional mandate: questions and answers on why we wrote to the Centers for Disease Control and Prevention. Subst Abus. 2019;40(4):466–468. doi:10.1080/08897077.2019.1635973
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich T, Chou R. No shortcuts to safer opioid prescribing. N Engl J Med. 2019;380(24):2285–2287. doi:10.1056/NEJMp1904190
   PubMed Web of Science ®Google Scholar
• Schatman ME, Ziegler SJ. Pain management, prescription opioid mortality, and the CDC: is the devil in the data? J Pain Res. 2017;10:2489–2495. doi:10.2147/JPR.S153322
   PubMed Web of Science ®Google Scholar
• Twillman R. AAPM CDC opioid guideline concerns [Internet letter]. American Academy of Pain Management; 2015. Available from: http://paindr.com/wp-content/uploads/2015/10/House-EC-CDC-Opioid-Guideline-Letter_AAPM-Twillman.pdf. Accessed February 2022.
   Google Scholar
• Duensing K, Twillman R, Ziegler S, et al. An examination of state and federal opioid analgesic and continuing education policies: 2016–2018. J Pain Res. 2020;13:2431–2442. doi:10.2147/JPR.S267448
   PubMed Web of Science ®Google Scholar
• Fudin J, Raouf M, Wegrzyn E, Schatman M. Safety concerns with centers for disease control opioid calculator. J Pain Res. 2018;11:1–4. doi:10.2147/JPR.S155444
   PubMed Web of Science ®Google Scholar
• Fudin J, Cleary JP, Schatman ME. The MEDD myth: the impact of pseudoscience on pain research and prescribing-guideline development. J Pain Res. 2016;9:153–156. doi:10.2147/JPR.S107794
   PubMed Web of Science ®Google Scholar
• Rennick A, Atkinson T, Cimino NM, et al. Variability in opioid equivalence calculations. Pain Med. 2016;17(5):892–898. doi:10.1111/pme.12920
   PubMed Web of Science ®Google Scholar
• Shaw K, Fudin J. Evaluation and comparison of online Equianalgesic opioid dose conversion calculators. Pract Pain Manag. 2013;13:61–66.
   Google Scholar
• Morphine milligram equivalents. Current applications and knowledge gaps, research opportunities, and future directions [Internet]. FDA; 2021. Available from: https://www.fda.gov/drugs/news-events-human-drugs/morphine-milligram-equivalents-current-applications-and-knowledge-gaps-research-opportunities-and. Accessed February 2022.
   Google Scholar
• Minnesota Department of Health. Opioids: perception of pain [Internet]. Minnesota Department of Health; 2020. Available from: https://www.health.state.mn.us/communities/opioids/prevention/painperception.html. Accessed February 2022.
   Google Scholar
• Gusovsky D. Americans consume vast majority of the world’s opioids. CNBC; 2016. Available from: https://www.cnbc.com/2016/04/27/americans-consume-almost-all-of-the-global-opioid-supply.html. Accessed February 2022.
   Google Scholar
• International Narcotics Control Board, Narcotic Drugs. Hydrocodone is a long-acting opioid formulation used to treat severe pain for a prolonged duration, and is taken orally. Oxycodone is a synthetic analgesic drug used to treat moderate to severe pain. International Narcotics Control Board, Narcotic Drugs: estimated World Requirements for 2011, Statistics for 2009, The United Nations, Vienna, Austria; 2010. Available from: https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2010/Narcotic_drugs_publication_2010.pdf. Accessed March 30, 2022.
   Google Scholar
• Duff JH, Tharakan SM, Davis-Castro CY, et al. Consumption of prescription opioids for pain: a comparison of opioid use in the United States and other countries [Internet]. Congressional Research Service; 2021. Available from: file:///Users/jeffreybettinger/Downloads/855318%20(1).pdf. Accessed February 2022.
   Google Scholar
• Mann B. Doctors and dentists still flooding US with opioid prescriptions [Internet]. NPR; 2020. Available from: https://www.npr.org/2020/07/17/887590699/doctors-and-dentists-still-flooding-u-s-with-opioid-prescriptions. Accessed February 2022.
   Google Scholar
• International Narcotics Control Board. Availability of internationally controlled drugs: ensuring adequate access for medical and scientific purposes [Internet]. INCB; 2015. Available from: http://www.incb.org/incb/en/publications/annual-reports/annual-report-supplement-2015.html. Accessed February 2022.
   Google Scholar
• Scholten WK, Christensen AE, Olesen AE, et al. Quantifying the adequacy of opioid analgesic consumption globally: an updated method and early findings. Am J Public Health. 2019;109(1):52–57.
   PubMed Web of Science ®Google Scholar
• Global atlas of palliative care at the end of life [Internet]. World Health Organization; 2014. Available from: https://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf. Accessed February 2022.
   Google Scholar
• International Narcotics Control Board. Recommendation 46. In: report of the International Narcotics Control Board for 2005. New York, NY: United Nations; 2006:97.
   Google Scholar
• Seya MJ, Gelders SF, Achara OU, Milani B, Scholten WK. A first comparison between the consumption of and the need for opioid analgesics at country, regional, and global levels. J Pain Palliat Care Pharmacother. 2011;25(1):6–18. doi:10.3109/15360288.2010.536307
   PubMedGoogle Scholar
• Rose ME. Are prescription opioids driving the opioid crisis? Assumptions vs Facts. Pain Med. 2018;19(4):793–807. doi:10.1093/pm/pnx048
   PubMed Web of Science ®Google Scholar
• DEA Diversion Control Division. Drug & chemical evaluation section: hydrocodone [Internet]. DEA; 2019. Available from: https://www.deadiversion.usdoj.gov/drug_chem_info/hydrocodone.pdf. Accessed February 2022.
   Google Scholar
• International Narcotics Control Board. Narcotic drugs: estimated world requirements for 2022. Statistics for 2020 [Internet]. INCB.org; 2022. Available from: https://www.incb.org/incb/en/narcotic-drugs/Technical_Reports/narcotic_drugs_reports.html. Accessed February 2022.
   Google Scholar
• Amsterdam JV, Van den Brink W. The misuse of prescription opioids: a threat for Europe? Curr Drug Abuse Rev. 2015;8(1):3–14. doi:10.2174/187447370801150611184218
   PubMedGoogle Scholar
• Chenaf C, Kabore J-L, Delorme J, et al. Prescription opioid analgesic use in France: trends and impact on morbidity-mortality. Eur J Pain. 2019;23(1):124–134. doi:10.1002/ejp.1291
   PubMed Web of Science ®Google Scholar
• Hider-Mlynarz K, Cavalie P, Maison P. Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe. Br J Clin Pharmacol. 2018;84(6):1324–1334. doi:10.1111/bcp.13564
   PubMed Web of Science ®Google Scholar
• Furlan AD, Chaparro LE, Irvin E, Mailis-Gagnon A. A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain. Pain Res Manage. 2011;16:337–351. doi:10.1155/2011/465281
   PubMed Web of Science ®Google Scholar
• Katz N. Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology. Clin J Pain. 2009;25(9):797–807. doi:10.1097/AJP.0b013e3181b12dec
   PubMed Web of Science ®Google Scholar
• Meske DS, Lawal OD, Elder H, et al. Efficacy of opioids versus placebo in chronic pain: a systematic review and meta-analysis of enriched enrollment randomized withdrawal trials. J Pain Res. 2018;11:923–934. doi:10.2147/JPR.S160255
   PubMed Web of Science ®Google Scholar
• Tayeb BO, Barreiro AE, Bradshaw YS, Chui KK, Carr DB. Durations of opioid, nonopioid drug, and behavioral clinical trials for chronic pain: adequate or inadequate? Pain Med. 2016;17(11):2036–2046. doi:10.1093/pm/pnw245
   PubMed Web of Science ®Google Scholar
• Buynak R, Rappaport SA, Rod K, et al. Long-term safety and efficacy of tapentadol extended release following up to 2 years of treatment in patients with moderate to severe, chronic pain: results from an open-label extension trial. Clin Ther. 2015;37(11):2420–2438. doi:10.1016/j.clinthera.2015.08.014
   PubMed Web of Science ®Google Scholar
• Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010;10(5):416–427. doi:10.1111/j.1533-2500.2010.00397.x
   PubMed Web of Science ®Google Scholar
• Hale M, Urdaneta V, Kirby MT, Xiang Q, Rauck R. Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids. J Pain Res. 2017;10:233–240. doi:10.2147/JPR.S120170
   PubMed Web of Science ®Google Scholar
• Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain. Arch Intern Med. 2000;160:853–860. doi:10.1001/archinte.160.6.853
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Farrar JT, Backonja MM, et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain. 2007;23:287–299. doi:10.1097/AJP.0b013e31802b582f
   PubMed Web of Science ®Google Scholar
• Friedmann N, Klutzaritz V, Webster L. Long-term safety of Remoxy® (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain. Pain Med. 2011;12(5):755–760. doi:10.1111/j.1526-4637.2011.01100.x
   PubMed Web of Science ®Google Scholar
• McIlwain H, Ahdieh H. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study. Am J Ther. 2005;12(2):106–112. doi:10.1097/01.mjt.0000139442.65914.f9
   PubMedGoogle Scholar
• Hale ME, Ma Y, Malamut R. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: safety, maintenance of analgesia, and abuse potential. J Opioid Manag. 2016;12(2):139–147. doi:10.5055/jom.2016.0326
   PubMedGoogle Scholar
• Taber L, Lynch SY, He E, Ripa SR. Long-term safety and effectiveness of once-daily, single entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain. Postgrad Med. 2016;128(1):23–33. doi:10.1080/00325481.2016.1134022
   PubMed Web of Science ®Google Scholar
• Hale ME, Zimmerman TR, Ma Y, Malamut R. Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain. J Opioid Manag. 2015;11(5):425–434. doi:10.5055/jom.2015.0292
   PubMedGoogle Scholar
• Wen W, Taber L, Lynch SY, He E, Ripa S. 12-month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain. J Opioid Manag. 2015;11(4):339–356. doi:10.5055/jom.2015.0283
   PubMedGoogle Scholar
• Nalamachu S, Rauck RL, Hale ME, Florete, Jr. OG, Robinson CY, Farr SJ. A long-term, open-label safety study of single-entity hydrocodone bitartrate extended release for the treatment of moderate to severe chronic pain. J Pain Res. 2014;7:669–678. doi:10.2147/JPR.S71536
   PubMed Web of Science ®Google Scholar
• Wallace M, Thipphawong J. Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain. Pain Med. 2010;11(10):1477–1488. doi:10.1111/j.1526-4637.2010.00956.x
   PubMed Web of Science ®Google Scholar
• Wallace M, Moulin DE, Rauck RL, et al. Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain. J Opioid Manag. 2009;5(2):97–105. doi:10.5055/jom.2009.0011
   PubMedGoogle Scholar
• Webster LR, Brewer R, Wang C, et al. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. J Pain Symptom Manage. 2010;40(5):734–746. doi:10.1016/j.jpainsymman.2010.05.004
   PubMed Web of Science ®Google Scholar
• Milligan K, Lanteri-Minet M, Borchert K, et al. Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain. 2001;2:197–204. doi:10.1054/jpai.2001.25352
   PubMed Web of Science ®Google Scholar
• Pascual ML, Fleming RR, Gana TJ, Vorsanger GJ. Open-label study of the safety and effectiveness of long-term therapy with extended-release tramadol in the management of chronic nonmaligant pain. Curr Med Res Opin. 2007;23(10):2531–2542. doi:10.1185/030079907X233179
   PubMed Web of Science ®Google Scholar
• Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain. The SPACE randomized clinical trial. JAMA. 2018;319:872–882. doi:10.1001/jama.2018.0899
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Benyamin R, Hirsch JA. Comments on Space randomized clinical trial by Krebs et al. Pain Phy. 2019;22:E139–E146. doi:10.36076/ppj/2019.22.E139
   PubMed Web of Science ®Google Scholar
• Schneider JP, Fudin J, Gudin J. Commentary on the KREBS SPACE trial. Pract Pain Manage. 2018;1(4):e34
   Google Scholar
• Gudin J, Kaufman AG, Datta S. Are opioids needed to treat chronic low back pain? A review of treatment options and analgesics in development. J Pain Res. 2020;13:1007–1022. doi:10.2147/JPR.S226483
   PubMed Web of Science ®Google Scholar